Donanemab Bests Aducanumab in Head-to-Head AD Trial

Patients with early, symptomatic Alzheimer's disease had significantly better amyloid clearance and plaque reduction after 6 months of treatment with donanemab compared with aducanumab.
Medscape Medical News